Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a biotechnology company that develops and markets transformative medicines for serious diseases, with a primary focus on cystic fibrosis (CF). Its marketed CF products include TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which treat patients ranging from 1 month to 6 years and older depending on the drug. The company also markets CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX for acute pain in adults. Additionally, Vertex has a pipeline of investigational therapies, such as VX-522 for CF, inaxaplin for APOL1-mediated kidney disease, VX-264 for Type 1 diabetes, VX-670 for myotonic dystrophy type 1, and VX-407 for autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals, and clinics.

Vertex Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol VRTX. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company's stock is part of the healthcare sector and is widely followed by investors interested in biotechnology and specialty pharmaceuticals.

Vertex Pharmaceuticals operates in the healthcare sector, specifically within the biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies for serious diseases, with a strong emphasis on genetic and rare conditions. Its expertise lies in areas such as cystic fibrosis, sickle cell disease, beta thalassemia, acute pain, and other specialty markets, leveraging advanced scientific approaches to create targeted treatments.

Vertex Pharmaceuticals is headquartered in Boston, Massachusetts, United States. Founded in 1989, the company operates globally, with a primary focus on specialty markets such as cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Its products are sold in various countries through specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals, and clinics, serving patients worldwide.

Vertex Pharmaceuticals generates revenue primarily by selling its approved medicines to specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals, and clinics. Its key revenue drivers are its cystic fibrosis portfolio, which includes products like TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. Additionally, the company earns revenue from CASGEVY for sickle cell disease and beta thalassemia, and JOURNAVX for acute pain. Vertex also invests in a pipeline of investigational therapies that may contribute future revenue upon approval.